333D Ltd (ASX:T3D) Shares Extend Losses: What's Happening?

Sonal Goyal

10 November 2026 07:04 PM AEDT

333D Ltd (ASX:T3D) Shares Extend Losses: What's Happening?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key highlights

333D shares were down 12.50% at $0.028 during the 10 November 2026 trading session.
Cash receipts from customers were $639,558 in the September 2026 quarter.
Net operating cash outflow fell to $62,827 from $250,085 in the June 2026 quarter, an improvement of approximately 75%.

333D Ltd (ASX:T3D) extended its losses during the 10 November 2026 trading session, with shares down 12.50% at $0.028. The S&P/ASX 200 was higher by 1.34%, or 121.20 points, at 9,150.90 over the same session. The company operates in digital asset creation and management, with a focus on healthcare applications. Its latest update was its Appendix 4C Cash Flow report and quarterly activities report for the quarter ended 30 September 2026, released on 29 October 2026.

Quarterly cash position

The Quarterly Report showed cash receipts from customers of $639,558 and total cash and digital asset holdings of $523,880 at quarter end. Net operating cash outflow reduced to $62,827, compared with $250,085 in the June 2026 quarter, which the company described as an improvement of approximately 75%.

The company said there was no change in the nature or scale of its activities during the quarter.

Product development and commercial progress

333D continued its focus on applied artificial intelligence and AI-enabled digital asset management. Its clinical software program uses de-identified cone-beam CT imaging data for potential applications in dental and maxillofacial imaging.

The company completed a model Training and evaluation milestone in the June quarter. The next step is pre-deployment optimisation and validation, after which it can assess commercialisation.

Sector context

Small technology companies with early-stage software and artificial intelligence products often trade on the timing of commercial milestones rather than current revenue. Investors in the sector pay close attention to how quickly a product can move from validation to market. The shares trade at under three cents, where percentage moves can be large, and the broader market was higher during the session.

Risks

Commercialisation of the clinical software depends on successful validation and optimisation, and there is no certainty about the timing or outcome of that work.

The pace of cash use and any future funding needs remain relevant to shareholders.

What to watch ahead

The main milestones are the start of pre-deployment optimisation and validation for the clinical software and further updates on the digital asset management platform. The December quarter cash flow report will also show whether the reduced cash outflow continues.

Final Word

333D's Trading session decline came alongside a quarterly report that showed lower operating cash use and steady product development. The company's commercial milestones in the coming months will shape its direction.

FAQs

Q: How much cash did 333D receive from customers?

A: Cash receipts from customers totalled $639,558 in the quarter ended 30 September 2026.

Q: How much cash does 333D hold?

A: The company reported total cash and digital asset holdings of $523,880 at quarter end.

Q: What is the clinical software being developed for?

A: The program uses de-identified cone-beam CT imaging data and has potential applications in dental and maxillofacial imaging.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.